

The "Quick" Clinical Trials Working Group (QWG) & the MTN: Thoughts Going Forward

Polly F. Harrison, PhD

Director

Alliance for Microbicide Development Silver Spring, MD, USA <u>www.microbicide.org</u>

Microbicide Trials Network (MTN) Annual Meeting—Plenary Session Washington, DC, 26 March 2007



QWG Mandate

Established following April 2004 meeting of **Microbicide Donors' Committee** to:

- promote exchange of knowledge, experience, data, ideas, & problems among investigators of current effectiveness trials
- •ensure that, if none of current late-stage candidate microbicides sufficiently effective for licensure, there will be maximal learning from design, implementation, analysis, & results of those trials



QWG Structure

Co-Chairs:

- •Salim Abdool Karim, Pro Vice-Chancellor for Research, University of KwaZulu-Natal
- •Janet Darbyshire, Director, Clinical Trials Unit, UK Medical Research Council

Membership:

•Investigators, current or planned microbicide effectiveness trials; statisticians; behavioral scientists; & guests as invited

Secretariat:

Alliance for Microbicide Development



QWG Meetings

Five meetings to date:

- •15-16 November 2004, Washington, DC, USA
- •10-11 May 2005, New York City, USA
- •16-17 November 2005, Chapel Hill, USA
- •27 April 2006, Cape Town, South Africa
- •23-24 January 2007, London, UK



QWG Meeting Structure & Focus

Each meeting includes:

- Update on status of trials being implemented/designed by each member
- Updates to now-standard set of tabular analytical summaries of protocol elements
- In-depth discussion of challenges, solutions, & topics identified as relevant & timely by co-chairs & members



Topics Addressed

- potential for meta-analysis of endpoint & safety data across studies of identical or similar products
- developing overarching "Super"-DMC
- MMCI & communication strategies
- use of biomarkers in trials
- determining incidence prior to & during trials
- statistical/ethical implications of current trial completion
- standard of care at trial sites
- statistical & behavioral issues around measuring/ maximizing adherence to protocol & product use
- proposal for alternative microbicide trial design activity



Going Forward

5th meeting explored statistical & ethical implications of completing current trials

4 potential scenarios: completed trial(s) show(s) . . .

- Harm
- No benefit or harm
- Benefit insufficient for licensure, or confusing result
- Benefit sufficiently compelling as public health and/or personal prevention intervention

Next QWG meeting to pursue, departing from forthcoming PopCouncil plan re Carraguard trials



Going Forward (cont.)

5th meeting also addressed feasibility & next steps for proposed "Alternative Trial Designs" activity

GOAL: To identify/explore novel designs for microbicide trials able to address challenges identified in QWG meetings & anticipated challenges

- 3 guest statisticians at 5th meeting made substantial contributions & will continue involvement
- QWG supports moving forward with this, conference calls since, planning underway

Preparation of prototype designs, analysis, discussion at next QWG meeting, June 2007 (TBC)



QWG/MTN Collaborations

Full membership in QWG & all its activities

Active collaboration in "Alternative Trial Designs" (& prototypes)

Identification/pursuit of issues through/around which QWG might enhance coordination of MTN clinical trials portfolio with other microbicide trials groups



Acknowledgments

Staff: Polly F. Harrison, PhD Director Franka N. des Vignes, PhD **Deputy Director** Latifa Boyce, MPH Communications Associate **Betsy Finley, MPH** Writer/Research Associate Carolyn Plescia, MHS Writer/Research Associate **Lois Holston** Administrative Associate

The work of the Alliance has been made possible by the dedication of its participants & contributions from the:

- Bill & Melinda Gates Foundation
- CONRAD
- International Partnership for Microbicides
- John M. Lloyd Foundation
- Moriah Fund
- Rockefeller Foundation
- US Agency for International Development
- William and Flora Hewlett Foundation
- and the generosity of private contributors.